ClinicalTrials.gg
RecruitingNCT07244393Updated Oct 7, 2026

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

A Phase 1 interventional study of Lutetium (177Lu) DGUL and Pembrolizumab in Metastatic Castration-resistant Prostate Cancer (mCRPC), sponsored by Cellbion Co., Ltd.. Recruiting at 1 site in South Korea. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Cellbion Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 7, 2026Now RecruitingFirst site in South Korea+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing Lutetium-177 in Prostatic Neoplasms — 8 open to participants now, 10 under way, none of them phase 3. Lutetium-177 · Prostatic Neoplasms.

Planned enrollment
8th of 14
30 · median 31
Started
2026
with 3 others
Phase 1
7 of 14
4 open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
Cellbion Co., Ltd.

Among the 14 studies testing Lutetium-177 in Prostatic Neoplasms, this one is the 8th largest by planned enrollment, is one of 4 that started in 2026, is one of 7 in phase 1, and was the 12th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 14 studies testing Lutetium-177 in Prostatic Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Lutetium-177

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 19 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Lutetium-177 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy.

Participants will:

Monotherapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals

Combination therapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals along with pembrolizumab up to 18 times at 6-week intervals

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged 19 years or older.
  • Patients with histopathologically or confirmed adenocarcinoma of the prostate, without neuroendocrine or small cell differentiation, who have disease documented by bone lesions/soft tissue lesions and are not eligible for curative treatment.
  • Patients with serum testosterone levels meeting castration levels (\< 50 ng/dL) at the screening visit.
  • Patients must have experienced disease progression following treatment for mCRPC with a second-generation androgen receptor signaling inhibitor therapy (e.g., abiraterone or enzalutamide).
  • Docetaxel treatment is allowed for localised prostate cancer and at mHSPC stage if more than 12 months have elapsed from the last dose of docetaxel, as long as no signs of failure or disease progression occurred during or immediately after such treatment.
  • Patients must be receiving hormone deprivation therapy limited to the use of LHRH agonists or LHRH antagonists throughout the study. For patients who have not undergone bilateral orchiectomy, medical castration with an LHRH agonist or antagonist must have been initiated at least 4 weeks prior to baseline and must be maintained for the entire study duration.
  • Patients with prostate specific membrane antigen (PSMA)-positive disease, with a maximum standardized uptake value (SUVmax) of at least 20 at a site of disease and greater than 10 at other disease sites measuring ≥ 10mm in longest diameter.
  • Patients with an (ECOG) performance status of ≤ 1.
  • Patients with a of at least 6 months.
  • Patients with adequate hematologic, renal, and liver function, confirmed by the following criteria:

    • (ANC) ≥ 1,500/μL (without granulocyte colony stimulating factor (G-CSF) administration within 2 weeks prior to baseline)
    • count ≥ 100,000/μL (without transfusion within 2 weeks prior to baseline)
    • ≥ 9.0 g/dL (without transfusion within 4 weeks prior to baseline)
    • Serum creatinine ≤ 1.8 mg/dL or creatinine clearance (CrCl) formula > 40 ml/min
    • (AST) and alanine transaminase (ALT) ≤ 2.5 times the (ULN), or ≤ 5 times the ULN for patients with confirmed liver metastasis
    • Total ≤ 1.5 times ULN (except in patients with Gilbert syndrome)
    • (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN
  • Patients who have AEs due to previous anticancer therapies must have recovered to ≤ Grade 1 or baseline. Patients with endocrine-related AEs who are adequately treated with hormone replacement or patients who have ≤ Grade 2 neuropathy are eligible.
  • Patients who voluntarily agree to participate in the clinical trial and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Known additional that is progressing or has required active treatment within the past 3 years (Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded).
  • Patients who have received chemotherapy, biological therapy, or immunotherapy for prostate cancer within 4 weeks from baseline (6 weeks in the case of nitrosoureas or mitomycin).
  • Any prior treatment with taxane chemotherapy for mCRPC.
  • Patients with history of stem cell transplantation (alloSCT), or solid organ transplantation.
  • Patients who have received high-dose chemotherapy requiring hematopoietic stem cell treatment, within 2 years from baseline.
  • Patients who have previously received PSMA-targeted treatment (e.g., radiotherapy, immunotherapy, or antibody-drug conjugate) or those treated with radiopharmaceuticals such as radium-223 within 6 months from baseline.
  • Patients who have previously received radiotherapy (RT) to the lung > 30 Gy within 6 months of the first dose.
  • Prior exposure to any anti-programmed cell death protein 1(), anti-programmed death ligand 1/2 (PD-L1/L2), or anti- cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody, or any other agent specifically targeting T cell co-stimulation or immune checkpoint pathways.
  • Diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study intervention.
  • Known active central nervous system (CNS) and/or carcinomatous meningitis. Patients with previously treated may enroll if they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks, as confirmed by repeat imaging during the study screening. They must also be clinically stable and must not have required steroid treatment for at least 4 weeks before receiving the first dose of the study intervention.
  • Patients with the following medical history or history of surgery/procedures:

    • Deep vein thrombosis (DVT) or pulmonary embolism (PE) within 1 year from baseline.
    • Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection within 6 months from baseline.
    • Acute coronary syndrome (unstable angina or myocardial infarction) within 6 months from baseline.
    • Major cerebrovascular disease, such as stroke, within 6 months from baseline.
    • General anesthesia or major surgery requiring respiratory assistance within 4 weeks from baseline (video-assisted thoracoscopic surgery or open-and-closed (ONC) surgery allowed within 2 weeks).
    • Active disease that has required systemic treatment in past 2 years except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid).
    • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Patients with the following conditions:

Class III or IV heart failure according to the (NYHA) classification.

  • Uncontrolled hypertension (systolic blood pressure (SBP) > 160 mm Hg or diastolic blood pressure (DBP) > 90 mm Hg).
  • cardiovascular abnormalities as determined by the investigator (e.g., (LVEF) \< 50%, clinically significant heart wall abnormalities, myocardial injury or corrected by Fridericia's formula (QTcF) > 450 msec for males or > 460 msec for females).
  • Uncontrolled cardiac arrhythmia.
  • Known positive (HIV) test or other uncontrolled active infectious diseases (e.g., /C).
  • Myelodysplastic syndrome (MDS).
  • Clinically significant urinary obstruction or hydronephrosis that may affect renal function as determined by the investigator.

    • Patients receiving nephrotoxic drugs (e.g., aminoglycosides).
    • Patients with severe claustrophobia not controlled by anxiolytics.
    • Patients with to any components of the product (IP)s.
    • Patients unwilling to use appropriate methods or abstain from intercourse during the clinical trial and for at least 4 months after discontinuation of the IPs if the patient's partner is capable of childbearing, or who do not agree to refrain from sperm donation during this period.
    • Patients who have received other IPs or undergone procedures involving investigational medical devices within 4 weeks from baseline.
    • Any other conditions deemed by the investigator as making the patient ineligible for clinical trial participation.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Monotherapy Arm

    Monotherapy Arm: 10 patients will receive Lutetium (177Lu) DGUL monotherapy.

    Drug: Lutetium (177Lu) DGUL

  • Experimental
    Combination Arm

    Combination Arm: 20 patients will receive Lutetium (177Lu) DGUL in combination with pembrolizumab.

    Drug: Lutetium (177Lu) DGUL · Drug: Pembrolizumab

Interventions

  • Lutetium (177Lu) DGUL will be administered in 4 doses at 6-week intervals (Q6W), and for patients showing good tolerance, additional 2 doses may be added, for a maximum of 6 doses.

  • pembrolizumab will be introduced at a dose of 400 mg every 6 weeks, beginning with the second cycle of Lutetium (177Lu) DGUL, and will continue for up to approximately 2 years (18 doses).

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Number of patients with treatment-emergent adverse events (TEAEs)

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  2. Number of patients with drug-related TEAEs

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  3. Adverse events (AEs)

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  4. Drug-related adverse reactions based on dose limited toxicity (DLT) definitions

    Time frame: From enrollment to 6-month follow-up after the end of treatment

Secondary outcomes

  1. Radiographic progression-free survivla (rPFS)

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  2. 1-year overall survivla (OS)

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  3. Objective response rate (ORR; confirmed complete response (CR) + partial response (PR))

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  4. Prostate specific antigen (PSA) response rate (>50% decrease compared to baseline PSA)

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  5. PSA PFS

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  6. Best PSA response through waterfall plot

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  7. Disease control rate (DCR)

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  8. Duration of response (DOR)

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  9. Tumor change rate (target lesion) through waterfall plot

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  10. Pain severity (numeric rating scale, NRS) and opioid analgesic use

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  11. Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 measures global health status, functional scales, and symptom scales. All scores range from 0 to 100. For functional and global health scales, higher scores indicate better functioning. For symptom scales, higher scores indicate worse symptoms.

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  12. Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module (EORTC QLQ-PR25)

    The EORTC QLQ-PR25 assesses urinary, bowel, hormonal treatment-related symptoms and sexual functioning. Scores range from 0 to 100. For symptom scales, higher scores indicate worse symptoms. For sexual functioning, higher scores indicate better functioning.

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  13. Quality of Life Assessed by the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)

    The EQ-5D-5L generates an index value reflecting health status, typically ranging from less than 0 (worse than death) to 1 (full health). Higher scores indicate better overall health. A Visual Analog Scale (0-100) may also be reported, where higher scores indicate better self-rated health.

    Time frame: From enrollment to 6-month follow-up after the end of treatment

  14. Time-Activity Curve for Lutetium (177Lu) DGUL

    The time-activity curve will be generated using serial imaging to quantify radioactivity kinetics of Lutetium (177Lu) DGUL in target tissues. Activity is measured in megabecquerels (MBq) over time.

    Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose

  15. Cumulative Activity of Lutetium (177Lu) DGUL

    Cumulative activity represents the total integrated activity (MBq·h) within organs or lesions over time, derived from the time-activity curve.

    Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose

  16. Residence Time of Lutetium (177Lu) DGUL

    Residence time is the time-integrated activity coefficient describing the average time (hours) that Lutetium (177Lu) DGUL remains in specific organs or lesions.

    Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose

  17. Effective Dose of Lutetium (177Lu) DGUL

    The effective dose will be calculated using organ residence times and standard dosimetry models. Effective dose is reported in millisieverts (mSv).

    Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose

  18. Area Under the Plasma Concentration-Time Curve (AUC) of Lutetium (177Lu) DGUL

    AUC represents the total systemic exposure to Lutetium (177Lu) DGUL over time. Reported in MBq·h or ng·h/mL depending on analytical method.

    Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose

  19. Peak Plasma Concentration (Cmax) of Lutetium (177Lu) DGUL

    Cmax is the highest observed plasma concentration of Lutetium (177Lu) DGUL. Reported in MBq/mL or ng/mL.

    Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose

  20. Time to Peak Plasma Concentration (Tmax) of Lutetium (177Lu) DGUL

    Tmax is the time at which Cmax occurs. Reported in hours.

    Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose

  21. Elimination Half-Life (T1/2) of Lutetium (177Lu) DGUL

    T1/2 represents the time required for the plasma concentration of Lutetium (177Lu) DGUL to decrease by 50%. Reported in hours.

    Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose

  22. Volume of Distribution (Vd) of Lutetium (177Lu) DGUL

    Vd is the apparent volume in which Lutetium (177Lu) DGUL is distributed throughout the body. Reported in liters (L).

    Time frame: Dosimetry of Lutetium (¹⁷⁷Lu) DGUL could have a time frame of "0, 30 minutes, 1, 2, 4, 6, 24, 48, 72, and 120 hours post-dose

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2029, 33 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 33 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Jul 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 24, 2025
StartActual
Jul 29, 2026was Dec 2025
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
1 site added — first site in South Korea
Show site
  • Seoul National University Hospital · Seoul, South Korea
Oct 5, 2026
Start date
Dec 2025→Jul 29, 2026 (actual)
Oct 5, 2026
Contact
Study contact changed: b•••@cellbion.co.kr · •••9815→b•••@cellbion.co.kr · •••3311. See the current contact
Oct 7, 2026
Show all 2 updates
  1. Oct 7, 2026
    Contact Study contact changed: b•••@cellbion.co.kr · •••9815→b•••@cellbion.co.kr · •••3311. See the current contact
  2. Oct 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in South Korea
    Show site
    • Seoul National University Hospital · Seoul, South Korea
    Start date Dec 2025→Jul 29, 2026 (now actual)
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07244393
Lead sponsor
Cellbion Co., Ltd.
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Jul 29, 2026
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Cellbi on
Contact
boyoung@cellbion.co.kr
8227433311

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion